Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neil Brickel

Psychiatry Saint Louis, MO Medical Doctor

NPI 1396716981 CMS profile 290342

11477 Olde Cabin Rd, Suite 210, Saint Louis, MO 63141

Open in the dashboard

General payments

$16,864

901 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neil Brickel of Saint Louis, MO is reported in the CMS Open Payments database as having received $16,864 across 901 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,836 139
2024 General $2,517 113
2023 General $3,410 204
2022 General $1,938 107
2021 General $1,911 111
2020 General $948 44
2019 General $3,303 183

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neil Brickel
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Neil Brickel were reported at $2,836. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Neil Brickel Psychiatry median Middle half National median
2019 $3,303 $184 $59–$605 $163
2020 $948 $119 $36–$372 $114
2021 $1,911 $143 $43–$576 $132
2022 $1,938 $153 $50–$590 $149
2023 $3,410 $170 $56–$651 $160
2024 $2,517 $179 $57–$673 $164
2025 $2,836 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $2,205 110 payments
  2. Otsuka America Pharmaceutical, Inc. $1,882 83 payments
  3. Corium, Inc. $1,571 78 payments
  4. AbbVie, Inc. $1,361 81 payments
  5. Sunovion Pharmaceuticals Inc. $1,208 57 payments
  6. Axsome Therapeutics, Inc. $951 39 payments
  7. Lundbeck LLC $835 42 payments
  8. Alkermes, Inc. $714 47 payments
  9. Vanda Pharmaceuticals Inc. $700 39 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $687 48 payments
  11. Other $4,749 277 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,801 896 payments
  2. Education $62 5 payments
Products named General payments · program years 2019–2025
  1. CAPLYTA $1,790 87 payments
  2. REXULTI Psychiatry $1,634 68 payments
  3. Azstarys $1,571 78 payments
  4. LATUDA $1,208 57 payments
  5. Auvelity $933 37 payments
  6. VRAYLAR Neuroscience $852 62 payments
  7. REXULTI Psychiatry $835 42 payments
  8. VRAYLAR Neuroscience $796 38 payments
  9. FANAPT $690 38 payments
  10. TRINTELLIX $536 33 payments
  11. Other $9,196 575 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,259

Median for Psychiatry: 574

Drug cost

$154,655

Median for Psychiatry: $27,624

Branded share of claims

41.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 18 $44,411
Vyvanse Lisdexamfetamine Dimesylate Brand 77 $30,754
Vraylar Cariprazine Hcl Brand 19 $27,551
Trintellix Vortioxetine Hydrobromide Brand 25 $14,421
Belsomra Suvorexant Brand 11 $4,807
Cymbalta Duloxetine Hcl Brand 15 $4,655
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 116 $4,460
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 57 $4,172
Lisdexamfetamine Dimesylate Generic 14 $3,587
Quetiapine Fumarate Er Quetiapine Fumarate Brand 13 $2,764

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$29,845

Medicare's payments for the services billed

Medicare patients

41

Average age 70

Services billed

360

26 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 71%
Arthritis 61%
Diabetes 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $436
$436 — —
Auvelity
  • Axsome Therapeutics, Inc. $325
$325 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $181
  • Lundbeck LLC $115
$296 — —
Azstarys
  • Corium, Inc. $214
$214 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $205
$205 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

901 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record